{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T10:39:18Z","timestamp":1787654358264,"version":"build-2736575974"},"reference-count":40,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,3]],"date-time":"2022-11-03T00:00:00Z","timestamp":1667433600000},"content-version":"vor","delay-in-days":1889,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["MOP-# 126076"],"award-info":[{"award-number":["MOP-# 126076"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004411","name":"Heart and Stroke Foundation of Canada","doi-asserted-by":"publisher","award":["G-13-0003091"],"award-info":[{"award-number":["G-13-0003091"]}],"id":[{"id":"10.13039\/100004411","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000038","name":"Natural Sciences and Engineering Research Council of Canada","doi-asserted-by":"publisher","award":["RGPIN\/5006-2015"],"award-info":[{"award-number":["RGPIN\/5006-2015"]}],"id":[{"id":"10.13039\/501100000038","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Pfizer, Inc."},{"DOI":"10.13039\/100013669","name":"Ionis Pharmaceuticals, Inc.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100013669","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Acasti"},{"name":"Abbott"},{"name":"Sunovion Tribute"},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1111\/jth.13759","type":"journal-article","created":{"date-parts":[[2017,6,20]],"date-time":"2017-06-20T14:42:39Z","timestamp":1497969759000},"page":"1834-1844","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Characterization of the I4399M variant of apolipoprotein(a): implications for altered prothrombotic properties of lipoprotein(a)"],"prefix":"10.1016","volume":"15","author":[{"given":"C.A.","family":"Scipione","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.T.","family":"McAiney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.J.","family":"Simard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z.A.","family":"Bazzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Gemin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Romagnuolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.L.","family":"Macrae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.A.","family":"Ari\u00ebns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.A.","family":"Hegele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Auld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.W.","family":"Gauld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.B.","family":"Boffa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.L.","family":"Koschinsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1111\/jth.13759_bb0010","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1056\/NEJMoa0902604","article-title":"Genetic variants associated with Lp(a) lipoprotein level and coronary disease","volume":"361","author":"Clarke","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1111\/jth.13759_bb0015","doi-asserted-by":"crossref","first-page":"36155","DOI":"10.1074\/jbc.M104789200","article-title":"Identification of a critical lysine residue in apolipoprotein B\u2010100 that mediates noncovalent interaction with apolipoprotein(a)","volume":"276","author":"Becker","year":"2001","journal-title":"J Biol Chem"},{"key":"10.1111\/jth.13759_bb0020","doi-asserted-by":"crossref","first-page":"10353","DOI":"10.1021\/bi962433d","article-title":"The solution phase interaction between apolipoprotein(a) and plasminogen inhibits the binding of plasminogen to a plasmin\u2010modified fibrinogen surface","volume":"36","author":"Sangrar","year":"1997","journal-title":"Biochemistry"},{"key":"10.1111\/jth.13759_bb0025","series-title":"Clinical Lipidology: A Companion to Braunwald's Heart Disease","first-page":"130","article-title":"Lipoprotein(a)","author":"Koschinsky","year":"2009"},{"key":"10.1111\/jth.13759_bb0030","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1021\/bi00455a007","article-title":"Apolipoprotein(a) size heterogeneity is related to variable number of repeat sequences in its mRNA","volume":"29","author":"Koschinsky","year":"1990","journal-title":"Biochemistry"},{"key":"10.1111\/jth.13759_bb0035","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/j.1365-2796.2012.02592.x","article-title":"Lipoprotein(a): resurrected by genetics","volume":"273","author":"Kronenberg","year":"2013","journal-title":"J Intern Med"},{"key":"10.1111\/jth.13759_bb0040","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1001\/jama.2009.801","article-title":"Genetically elevated lipoprotein(a) and increased risk of myocardial infarction","volume":"301","author":"Kamstrup","year":"2009","journal-title":"JAMA"},{"key":"10.1111\/jth.13759_bb0045","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.1161\/ATVBAHA.107.141291","article-title":"A polymorphism in the protease\u2010like domain of apolipoprotein(a) is associated with severe coronary artery disease","volume":"27","author":"Luke","year":"2007","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1111\/jth.13759_bb0050","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1016\/j.jacc.2012.01.078","article-title":"Apolipoprotein(a) genetic sequence variants associated with systemic atherosclerosis and coronary atherosclerotic burden but not with venous thromboembolism","volume":"60","author":"Helgadottir","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"10.1111\/jth.13759_bb0055","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1161\/CIRCULATIONAHA.116.024611","article-title":"LPA gene, ethnicity, and cardiovascular events","volume":"135","author":"Lee","year":"2017","journal-title":"Circulation"},{"key":"10.1111\/jth.13759_bb0060","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.atherosclerosis.2008.07.019","article-title":"Polymorphism in the apolipoprotein(a) gene, plasma lipoprotein(a), cardiovascular disease, and low\u2010dose aspirin therapy","volume":"203","author":"Chasman","year":"2009","journal-title":"Atherosclerosis"},{"key":"10.1111\/jth.13759_bb0065","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.thromres.2014.01.024","article-title":"Lipoprotein (a), LPA Ile4399Met, and fibrin clot properties","volume":"133","author":"Rowland","year":"2014","journal-title":"Thromb Res"},{"key":"10.1111\/jth.13759_bb0070","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.atherosclerosis.2009.09.077","article-title":"The I4399M variant of apolipoprotein(a) is associated with increased oxidized phospholipids on apolipoprotein B\u2010100 particles","volume":"209","author":"Arai","year":"2010","journal-title":"Atherosclerosis"},{"key":"10.1111\/jth.13759_bb0075","doi-asserted-by":"crossref","first-page":"23260","DOI":"10.1074\/jbc.M302780200","article-title":"Inhibition of plasminogen activation by lipoprotein(a): critical domains in apolipoprotein(a) and mechanism of inhibition on fibrin and degraded fibrin surfaces","volume":"278","author":"Hancock","year":"2003","journal-title":"J Biol Chem"},{"key":"10.1111\/jth.13759_bb0080","doi-asserted-by":"crossref","first-page":"5044","DOI":"10.1021\/bi00234a029","article-title":"Apolipoprotein(a): expression and characterization of a recombinant form of the protein in mammalian cells","volume":"30","author":"Koschinsky","year":"1991","journal-title":"Biochemistry"},{"key":"10.1111\/jth.13759_bb0085","doi-asserted-by":"crossref","first-page":"11649","DOI":"10.1074\/jbc.M114.611988","article-title":"Lipoprotein(a) catabolism is regulated by proprotein convertase subtilisin\/kexin type 9 through the low density lipoprotein receptor","volume":"290","author":"Romagnuolo","year":"2015","journal-title":"J Biol Chem"},{"key":"10.1111\/jth.13759_bb0090","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1038\/ncpcardio1326","article-title":"APOA5 genetic variants are markers for classic hyperlipoproteinemia phenotypes and hypertriglyceridemia","volume":"5","author":"Wang","year":"2008","journal-title":"Nat Clin Pract Cardiovasc Med"},{"key":"10.1111\/jth.13759_bb0095","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1016\/S0022-2275(20)37461-7","article-title":"Differences in Lp[a] concentrations and apo[a] polymorphs between black and white Americans","volume":"37","author":"Marcovina","year":"1996","journal-title":"J Lipid Res"},{"key":"10.1111\/jth.13759_bb0100","doi-asserted-by":"crossref","first-page":"5151","DOI":"10.1021\/bi00015a028","article-title":"Antifibrinolytic effect of recombinant apolipoprotein(a) in vitro is primarily due to attenuation of tPA\u2010mediated Glu\u2010plasminogen activation","volume":"34","author":"Sangrar","year":"1995","journal-title":"Biochemistry"},{"key":"10.1111\/jth.13759_bb0105","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1111\/jth.13278","article-title":"Procoagulant changes in fibrin clot structure in patients with cirrhosis are associated with oxidative modifications of fibrinogen","volume":"14","author":"Hugenholtz","year":"2016","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.13759_bb0110","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1002\/jcc.20289","article-title":"Scalable molecular dynamics with NAMD","volume":"26","author":"Phillips","year":"2005","journal-title":"J Computational Chem"},{"key":"10.1111\/jth.13759_bb0115","doi-asserted-by":"crossref","first-page":"15777","DOI":"10.1021\/bi00048a023","article-title":"Analysis of the proteolytic activity of a recombinant form of apolipoprotein(a)","volume":"34","author":"Gabel","year":"1995","journal-title":"Biochemistry"},{"key":"10.1111\/jth.13759_bb0120","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1063\/1.445869","article-title":"Comparison of simple potential functions for simulating liquid water","volume":"79","author":"Jorgensen","year":"1983","journal-title":"J Chem Phys"},{"key":"10.1111\/jth.13759_bb0125","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1002\/jcc.20035","article-title":"Development and testing of a general amber force field","volume":"25","author":"Wang","year":"2004","journal-title":"J Computational Chem"},{"key":"10.1111\/jth.13759_bb0130","doi-asserted-by":"crossref","first-page":"2856","DOI":"10.1038\/nprot.2006.468","article-title":"In\u2010gel digestion for mass spectrometric characterization of proteins and proteomes","volume":"1","author":"Shevchenko","year":"2006","journal-title":"Nat Protoc"},{"key":"10.1111\/jth.13759_bb0135","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/0014-5793(94)00737-3","article-title":"Carboxyl\u2010terminal truncation of apolipoproteinB\u2010100 inhibits lipoprotein(a) particle formation","volume":"350","author":"Gabel","year":"1994","journal-title":"FEBS Lett"},{"key":"10.1111\/jth.13759_bb0140","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1139\/o00-065","article-title":"Characterization of the interaction of recombinant apolipoprotein(a) with modified fibrinogen surfaces and fibrin clots","volume":"78","author":"Sangrar","year":"2000","journal-title":"Biochem Cell Biol"},{"key":"10.1111\/jth.13759_bb0145","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1111\/j.1538-7836.2008.03183.x","article-title":"Apolipoprotein(a) inhibits the conversion of Glu\u2010plasminogen to Lys\u2010plasminogen: a novel mechanism for lipoprotein(a)\u2010mediated inhibition of plasminogen activation","volume":"6","author":"Feric","year":"2008","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.13759_bb0150","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1161\/01.CIR.96.5.1612","article-title":"Apolipoprotein(a) attenuates endogenous fibrinolysis in the rabbit jugular vein thrombosis model in vivo","volume":"96","author":"Biemond","year":"1997","journal-title":"Circulation"},{"key":"10.1111\/jth.13759_bb0155","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1111\/j.1538-7836.2005.01540.x","article-title":"Apo(a) promotes thrombosis in a vascular injury model by a mechanism independent of plasminogen","volume":"3","author":"Sha","year":"2005","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.13759_bb0160","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1111\/j.1538-7836.2007.02637.x","article-title":"Altered fibrin clot structure in patients with advanced coronary artery disease: a role of C\u2010reactive protein, lipoprotein(a) and homocysteine","volume":"5","author":"Undas","year":"2007","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.13759_bb0165","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1111\/j.1538-7836.2006.01903.x","article-title":"Lipoprotein(a) as a modifier of fibrin clot permeability and susceptibility to lysis","volume":"4","author":"Undas","year":"2006","journal-title":"J Thromb Haemost"},{"key":"10.1111\/jth.13759_bb0170","doi-asserted-by":"crossref","first-page":"161","DOI":"10.2174\/187152508784871963","article-title":"The biochemical and physical process of fibrinolysis and effects of clot structure and stability on the lysis rate","volume":"6","author":"Weisel","year":"2008","journal-title":"Cardiovasc Hematol Agents Med Chem"},{"key":"10.1111\/jth.13759_bb0175","doi-asserted-by":"crossref","first-page":"3008","DOI":"10.1182\/blood-2002-08-2527","article-title":"Elevated prothrombin results in clots with an altered fiber structure: a possible mechanism of the increased thrombotic risk","volume":"101","author":"Wolberg","year":"2003","journal-title":"Blood"},{"key":"10.1111\/jth.13759_bb0180","doi-asserted-by":"crossref","first-page":"24259","DOI":"10.1016\/S0021-9258(18)35759-4","article-title":"The effect of fibrin structure on fibrinolysis","volume":"267","author":"Gabriel","year":"1992","journal-title":"J Biol Chem"},{"key":"10.1111\/jth.13759_bb0185","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0022-2275(20)38529-1","article-title":"Effect of oxidation on the properties of apolipoproteins A\u2010I and A\u2010II","volume":"29","author":"Anantharamaiah","year":"1988","journal-title":"J Lipid Res"},{"key":"10.1111\/jth.13759_bb0190","doi-asserted-by":"crossref","first-page":"8168","DOI":"10.1021\/bi00083a017","article-title":"Functional methionines in the collagen\/gelatin binding domain of plasma fibronectin: effects of chemical modification by chloramine T","volume":"32","author":"Miles","year":"1993","journal-title":"Biochemistry"},{"key":"10.1111\/jth.13759_bb0195","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1055\/s-0037-1616056","article-title":"The Kringle V\u2010protease domain is a fibrinogen binding region within Apo(a)","volume":"86","author":"Xue","year":"2001","journal-title":"Thromb Haemost"},{"key":"10.1111\/jth.13759_bb0200","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1172\/JCI118765","article-title":"Evidence that the fibrinogen binding domain of Apo(a) is outside the lysine binding site of kringle IV\u201010: a study involving naturally occurring lysine binding defective lipoprotein(a) phenotypes","volume":"98","author":"Klezovitch","year":"1996","journal-title":"J Clin Invest"},{"key":"10.1111\/jth.13759_bb0205","doi-asserted-by":"crossref","first-page":"835","DOI":"10.2217\/clp.10.68","article-title":"Lipid oxidation by hypochlorous acid: chlorinated lipids in atherosclerosis and myocardial ischemia","volume":"5","author":"Ford","year":"2010","journal-title":"Clin Lipidol"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjth.13759","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783622008522?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783622008522?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/jth.13759\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T03:17:04Z","timestamp":1761535024000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783622008522"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9]]},"references-count":40,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2017,9]]}},"alternative-id":["S1538783622008522"],"URL":"https:\/\/doi.org\/10.1111\/jth.13759","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2017,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Characterization of the I4399M variant of apolipoprotein(a): implications for altered prothrombotic properties of lipoprotein(a)","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1111\/jth.13759","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2017 International Society on Thrombosis and Haemostasis. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}